Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1

Interventions

Sunitinib 2tucatinib 1testosterone 17 beta-cypionate 1pembrolizumab 1dodecyl maltoside 1cabozantinib 1Urinary Diversion 1Trastuzumab 1Testosterone Propionate 1Standard of Care 1Saline Solution 1Radiosurgery 1Psychiatric Nursing 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Methyltestosterone 1Lidocaine 1Immune Checkpoint Inhibitors 1Fulvestrant 1Doxycycline 1Cystectomy 1Control Groups 1Ado-Trastuzumab Emtansine 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urologic Neoplasms × Urinary Diversion × Clear all
NCT05241340 2025-10-24

RAD-VACCINE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡